£22.5M
The Series A round was backed by Syncona Investment Management and Cambridge Innovation Capital to support pipeline progression and team expansion.
Mosaic Therapeutics
Mosaic Therapeutics develops targeted oncology treatments using advanced computational methods and cancer genomics.
£22.5MTotal raised
Mosaic Therapeutics develops targeted oncology therapies by combining advanced computational methods with next-generation cancer models. The firm builds upon research originating from the Wellcome Sanger Institute and the Netherlands Cancer Institute.
Categories
Founders
MG
Mathew Garnett
Senior Group Leader
EV
Emile Voest
Professor of Medical Oncology
AI
Adrian Ibrahim
Head of Technology Translation